Ascendis Pharma A/S (NASDAQ:ASND) Posts Earnings Results

Ascendis Pharma A/S (NASDAQ:ASND) posted its quarterly earnings results on Wednesday. The biotechnology company reported ($0.68) EPS for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.64, Zacks reports.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ ASND opened at $126.14 on Thursday. The company has a market cap of $7.66 billion, a P/E ratio of -15.61 and a beta of 0.64. The firm’s fifty day moving average is $131.98 and its two-hundred day moving average is $132.22. Ascendis Pharma A/S has a 52-week low of $111.09 and a 52-week high of $161.00.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ASND. Oppenheimer cut their price target on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating on the stock in a report on Friday, November 15th. Cantor Fitzgerald reiterated an “overweight” rating and set a $170.00 price target on shares of Ascendis Pharma A/S in a report on Tuesday. Wedbush reiterated an “outperform” rating and set a $181.00 price target on shares of Ascendis Pharma A/S in a report on Friday, November 15th. JPMorgan Chase & Co. raised their target price on shares of Ascendis Pharma A/S from $165.00 to $167.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. Finally, TD Cowen dropped their target price on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a report on Friday, November 15th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $191.57.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.